Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs ...

It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said its experimental immune therapy nipocalimab cleared a major clinical ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

Which of the statements about the 2025 American College of Rheumatology guideline for the treatment of systemic lupus ...

Johnson & Johnson JNJ announced that the phase IIb JASMINE study, which evaluated its pipeline candidate, nipocalimab, for ...

Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...

Lupus affects women at disproportionately high rates— roughly 9 out of 10 patients are female —and research consistently ...

NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Today, the Lupus Research Alliance, the world's largest private funder of lupus research, announced the first recipients of the Mechanistic Clinical Award. This ...